Steady-state pharmacokinetics of nevirapine in HIV-1 infected adults in India

Journal of the International Association of Physicians in AIDS Care

Volumn 6, Issue 4, 2007, Pages 251-254

  Ramachandran, Geetha ^a   Hemanthkumar, A K ^a   Rajasekaran, S ^b   Padmapriyadarsini, C ^a   Narendran, G ^a   Anitha, S ^a   Subramanyam, Sudha ^a   Kumaraswami, V ^a   Swaminathan, Soumya ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b Government Hospital for Thoracic Medicine   (India)

Author keywords

BMI; immune status; India; nevirapine; pharmacokinetics; sex

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE;

ADULT; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INDIA;

ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; INDIA; NEVIRAPINE;

EID: 62949189691     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109707301344     Document Type: Article

References (19)

1. World Health Organization. Scaling Up Antiretroviral Therapy in Resource Limited Settings: Treatment Guidelines for a Public Health Approach-2003 Revision. Geneva: World Health Organization ; 2003. Available at: http://www.who.int/hiv/pub/prev-care/en/arvrevision2003en.pdf.
2. Kumarasamy N., Solomon S., Chaguturu SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy i (Pubitemid 41580000)
3. Calmy A., Pinoges L., Szumilin E., et al. Generic fixed dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006 ; 20: 1163-1169. (Pubitemid 43786105)
4. Laurent C., Kouanfack C., Koulla-Shiro S., et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004 ; 364: 29-34. (Pubitemid 38968622)
5. Pujari SN, Patel AK, Naik E., et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immun Defic Syndr. 2004 ; 37: 1566-1569. (Pubitemid 39658193)
6. Phair JP, Flexner CW Factors Associated With Pharmacokinetic Variability in HIV-Infected Patients. Chicago, IL: Northwestern University, Feinberg School of Medicine, Office of Continuing Medical Education, iMedOptions ; 2004.
7. La Porte C., Burger D., Gyssens I., Sprenger H., Koopman P. Gender differences in Nevirapine pharmacokinetics, fact or fiction? Program and abstracts of the 4th International Workshop on Clinical Pharmacology in HIV therapy ; 2003 ; France.
8. Keating J., Bjarnason I., Somasundaram S., et al. Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhea. Gut. 1995 ; 37: 623-629.
9. Moyer TP, Temesgen Z., Enger R., et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem. 1999 ; 45: 1465-1476. (Pubitemid 29418999)
10. National Institute of Nutrition (Indian Council of Medical Research). Hyderabad, India, 2005.
11. Kappelhoff BS, van Leth F., Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther. 2005 ; 10: 489-498. (Pubitemid 41059195)
12. Donnerer J., Kronawetter M., Kapper A., Haas I., Kessler HH Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Pharmacology. 2003 ; 69: 197-204. (Pubitemid 37465137)
13. Havlir D., Cheeseman SH, McLaughlin M., et al. High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995 ; 171: 537-545.
14. Hosseinipour MC, Corbett A., Kanyama C., et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian subjects. 12th Conference in Retroviruses and Opportunistic Infections ; 2005 ; Boston.
15. van Heeswijk RPG, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1 infected individuals. AIDS. 2000 ; 14: F77 - F82.
16. van Praag RME, van Weert ECM, van Heeswijk RPG, et al. Stable concentrations of zidovudine, stavudine, lamivudine, abacavir and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother. 2002 ; 46: 896-899. (Pubitemid 34157685)
17. Ribera E., Pou L., Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immun Defic Syndr. 2001 ; 28: 450-453. (Pubitemid 34033196)
18. de Maat MM, Huitema AD, Mulder JW, Meenhorst PC, van Gorp EC, Beijnen JH Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1 infected individuals. Br J Clin Pharmacol. 2002 ; 54: 378-385. (Pubitemid 35334950)
19. Gurumurthy P., Ramachandran G., Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other anti-TB drugs in patients with advanced HIV disease. Antimicrob Agents Chemother. 2004 ; 48: 4473-4475. (Pubitemid 39434921)